Skip to main content
Erschienen in: CNS Drugs 6/2007

01.06.2007 | Current Opinion

Long-Acting Formulations of Atypical Antipsychotics

Time to Reconsider When to Introduce Depot Antipsychotics

verfasst von: Dr Pierre Chue, Robin Emsley

Erschienen in: CNS Drugs | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

The current availability of a long-acting injectable formulation of risperidone and the potential future availability of long-acting formulations of other atypical antipsychotics (such as paliperidone) should prompt a reconsideration of at what stage in the treatment of schizophrenia such long-acting agents should be introduced. At present, long-acting formulations, particularly of conventional antipsychotics (depots), are usually reserved for patients with chronic schizophrenia who are at high-risk of noncompliance. Recent and increasing data from other patient groups, such as those with first-episode psychosis, suggest that long-acting risperidone is associated with good efficacy and tolerability leading to high patient acceptance, and treatment continuation rates that are greater than with oral antipsychotics. The benefits of an atypical antipsychotic coupled with the assurance of medication delivery in the form of a long-acting injection imply that these novel formulations should be considered in first-episode patients, for whom optimal outcome is frequently compromised by early treatment discontinuation and poor adherence.
Literatur
1.
Zurück zum Zitat Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 2006; 36(10): 1349–62PubMedCrossRef Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 2006; 36(10): 1349–62PubMedCrossRef
2.
Zurück zum Zitat Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R, et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psych Res 2007; 41(8): 659–66CrossRef Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R, et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psych Res 2007; 41(8): 659–66CrossRef
3.
Zurück zum Zitat Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006; 163(4): 743–5PubMedCrossRef Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006; 163(4): 743–5PubMedCrossRef
4.
Zurück zum Zitat Robinson DG, Woerner MG, Delman HM, et al. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005; 31(3): 705–22PubMedCrossRef Robinson DG, Woerner MG, Delman HM, et al. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005; 31(3): 705–22PubMedCrossRef
5.
Zurück zum Zitat Bradford DW, Perkins DO, Lieberman JA. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 2003; 63(21): 2265–83PubMedCrossRef Bradford DW, Perkins DO, Lieberman JA. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 2003; 63(21): 2265–83PubMedCrossRef
6.
Zurück zum Zitat Malla A, Norman R, Schmitz N, et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med 2006; 36(5): 649–58PubMedCrossRef Malla A, Norman R, Schmitz N, et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med 2006; 36(5): 649–58PubMedCrossRef
7.
Zurück zum Zitat McEvoy JP, Johnson J, Perkins D, et al. Insight in first-episode psychosis. Psychol Med 2006; 36(10): 1385–93PubMedCrossRef McEvoy JP, Johnson J, Perkins D, et al. Insight in first-episode psychosis. Psychol Med 2006; 36(10): 1385–93PubMedCrossRef
8.
Zurück zum Zitat Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002; 57(2–3): 209–19PubMedCrossRef Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002; 57(2–3): 209–19PubMedCrossRef
9.
Zurück zum Zitat Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psych 2003; 64: 24–33 Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psych 2003; 64: 24–33
10.
Zurück zum Zitat Schooler N. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003; 64: 14–7PubMedCrossRef Schooler N. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003; 64: 14–7PubMedCrossRef
11.
Zurück zum Zitat Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994; 47(5): 741–73PubMedCrossRef Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994; 47(5): 741–73PubMedCrossRef
12.
Zurück zum Zitat McEvoy JP. Risks versus benefits of different types of longacting injectable antipsychotics. J Clin Psychiatry 2006; 67(5): 15–8PubMed McEvoy JP. Risks versus benefits of different types of longacting injectable antipsychotics. J Clin Psychiatry 2006; 67(5): 15–8PubMed
13.
Zurück zum Zitat Canadian Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry 2005; 50: 7–57S Canadian Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry 2005; 50: 7–57S
14.
Zurück zum Zitat Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005; 39 (1–2): 1–30CrossRef Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005; 39 (1–2): 1–30CrossRef
15.
Zurück zum Zitat American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2nd ed. Arlington (VA): American Psychiatric Association, 2004 American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2nd ed. Arlington (VA): American Psychiatric Association, 2004
16.
Zurück zum Zitat Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004; 65(4): 500–8PubMedCrossRef Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004; 65(4): 500–8PubMedCrossRef
17.
Zurück zum Zitat Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64: 5–19 Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64: 5–19
18.
Zurück zum Zitat Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8(1): 55–66 Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8(1): 55–66
19.
Zurück zum Zitat Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003; 63(5): 493–512PubMedCrossRef Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003; 63(5): 493–512PubMedCrossRef
20.
Zurück zum Zitat Moller HJ. Antipsychotic agents: gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Eur Psychiatry 2005; 20(5–6): 379–85PubMedCrossRef Moller HJ. Antipsychotic agents: gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Eur Psychiatry 2005; 20(5–6): 379–85PubMedCrossRef
21.
Zurück zum Zitat Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003; 64: 34–40PubMed Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003; 64: 34–40PubMed
22.
Zurück zum Zitat Dursun SJ. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia. J Psychopharmacol 2005; 19(5): 3–4CrossRef Dursun SJ. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia. J Psychopharmacol 2005; 19(5): 3–4CrossRef
23.
Zurück zum Zitat Keith SJ, et al. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry 2004; 65(1): 120–31PubMedCrossRef Keith SJ, et al. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry 2004; 65(1): 120–31PubMedCrossRef
24.
Zurück zum Zitat Jarboe KS, Littrell K, Tugrul K. Long-acting injectable risperidone: an emerging tool in schizophrenia treatment. J Psychosoc Nurs Ment Health Serv 2005; 43(12): 25–33PubMed Jarboe KS, Littrell K, Tugrul K. Long-acting injectable risperidone: an emerging tool in schizophrenia treatment. J Psychosoc Nurs Ment Health Serv 2005; 43(12): 25–33PubMed
25.
Zurück zum Zitat Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new longacting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004; 14(2): 87–92PubMedCrossRef Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new longacting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004; 14(2): 87–92PubMedCrossRef
26.
Zurück zum Zitat Love RC. Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 2002; 59: S10–5PubMed Love RC. Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 2002; 59: S10–5PubMed
27.
Zurück zum Zitat Chen EY, Harrison G, Standen PJ. Management of first episode psychotic illness in Afro-Caribbean patients. Br J Psychiatry 1991; 158: 517–22PubMedCrossRef Chen EY, Harrison G, Standen PJ. Management of first episode psychotic illness in Afro-Caribbean patients. Br J Psychiatry 1991; 158: 517–22PubMedCrossRef
28.
Zurück zum Zitat Valenstein M, Copeland LA, Owen R, et al. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001; 62(7): 545–51PubMedCrossRef Valenstein M, Copeland LA, Owen R, et al. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001; 62(7): 545–51PubMedCrossRef
29.
Zurück zum Zitat Tiihonen J, Walhbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333(7561): 224–7PubMedCrossRef Tiihonen J, Walhbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333(7561): 224–7PubMedCrossRef
30.
Zurück zum Zitat Kane JM, Rifkin A, Quitkin F, et al. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982; 39: 70–3PubMedCrossRef Kane JM, Rifkin A, Quitkin F, et al. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982; 39: 70–3PubMedCrossRef
31.
Zurück zum Zitat Harrison TS, Goa LA. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 2004; 18(2): 113–32PubMedCrossRef Harrison TS, Goa LA. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 2004; 18(2): 113–32PubMedCrossRef
32.
Zurück zum Zitat Chue P. Risperidone long-acting injection. Expert Rev Neurotherapeutics 2003; 3(4): 89–100CrossRef Chue P. Risperidone long-acting injection. Expert Rev Neurotherapeutics 2003; 3(4): 89–100CrossRef
33.
Zurück zum Zitat Thompson S, Rey JA. Risperdal consta: the first long-acting atypical antipsychotic agent. P&T 2004; 29(9): 555–62 Thompson S, Rey JA. Risperdal consta: the first long-acting atypical antipsychotic agent. P&T 2004; 29(9): 555–62
34.
Zurück zum Zitat Faludi G. The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia [in Hungarian]. Neuropsychopharmacol Hung 2005; 7(1): 22–7PubMed Faludi G. The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia [in Hungarian]. Neuropsychopharmacol Hung 2005; 7(1): 22–7PubMed
35.
Zurück zum Zitat Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 2004; 26(12): 1994–2002PubMedCrossRef Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 2004; 26(12): 1994–2002PubMedCrossRef
36.
Zurück zum Zitat Lemon M. Risperidone long-acting injection: a brief overview. S D J Med 2004; 57(5): 171–2PubMed Lemon M. Risperidone long-acting injection: a brief overview. S D J Med 2004; 57(5): 171–2PubMed
37.
Zurück zum Zitat Love RC, Conley RJ. Long-acting risperidone injection. Am J Health Syst Pharm 2004; 61(17): 1792–800PubMed Love RC, Conley RJ. Long-acting risperidone injection. Am J Health Syst Pharm 2004; 61(17): 1792–800PubMed
38.
Zurück zum Zitat Ehret MJ, Fuller MA. Long-acting injectable risperidone. Ann Pharmacother 2004; 38(12): 2122–7PubMedCrossRef Ehret MJ, Fuller MA. Long-acting injectable risperidone. Ann Pharmacother 2004; 38(12): 2122–7PubMedCrossRef
39.
Zurück zum Zitat Curran MP. Long-acting injectable risperidone. Int J Clinical Psychopharmacology 2006; 14(2): 107–25 Curran MP. Long-acting injectable risperidone. Int J Clinical Psychopharmacology 2006; 14(2): 107–25
40.
Zurück zum Zitat Parellada E. Clinical experience and management considerations with long-acting risperidone. Curr Med Res Opin 2006; 22(2): 241–55PubMedCrossRef Parellada E. Clinical experience and management considerations with long-acting risperidone. Curr Med Res Opin 2006; 22(2): 241–55PubMedCrossRef
41.
Zurück zum Zitat Martin SD, Libretto SE, Pratt DJ, et al. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Curr Med Res Opin 2003; 19(4): 298–305PubMedCrossRef Martin SD, Libretto SE, Pratt DJ, et al. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Curr Med Res Opin 2003; 19(4): 298–305PubMedCrossRef
42.
Zurück zum Zitat Marder SR, Conley R, Ereshefsky L, et al. Clinical guidelines: dosing and switching strategies for long-acting risperidone. J Clin Psychiatry 2003; 64: 41–6PubMed Marder SR, Conley R, Ereshefsky L, et al. Clinical guidelines: dosing and switching strategies for long-acting risperidone. J Clin Psychiatry 2003; 64: 41–6PubMed
43.
Zurück zum Zitat Taylor DM, Young CL, Mace S, et al. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004; 65(8): 1076–83PubMedCrossRef Taylor DM, Young CL, Mace S, et al. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004; 65(8): 1076–83PubMedCrossRef
44.
Zurück zum Zitat Marsand P, Gupta S. Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging 2003; 20(15): 1099–110CrossRef Marsand P, Gupta S. Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging 2003; 20(15): 1099–110CrossRef
45.
Zurück zum Zitat Chue P. Long-acting risperidone injection: efficacy, safety and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat 2007. E-pub Chue P. Long-acting risperidone injection: efficacy, safety and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat 2007. E-pub
46.
Zurück zum Zitat Keith S, Nick B, Emsley R, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 2004; 55(9): 997–1005PubMedCrossRef Keith S, Nick B, Emsley R, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 2004; 55(9): 997–1005PubMedCrossRef
47.
Zurück zum Zitat Parellada E, Andrezina R, Milanova V, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005; 19: 5–14PubMedCrossRef Parellada E, Andrezina R, Milanova V, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005; 19: 5–14PubMedCrossRef
48.
Zurück zum Zitat Saleem P, Firmino H, Parellada E, et al. Young patients (18–30 years) with schizophrenia and schizoaffective disorder: results of direct switching to long-acting injectable risperidone (StoRMi trial) [abstract]. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7–13: Davos Saleem P, Firmino H, Parellada E, et al. Young patients (18–30 years) with schizophrenia and schizoaffective disorder: results of direct switching to long-acting injectable risperidone (StoRMi trial) [abstract]. 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7–13: Davos
49.
Zurück zum Zitat Lasser R, Bossie CA, Zhu Y, et al. Long-acting risperidone in young adults with schizophrenia or schizoaffective disorder [abstract]. 157th American Psychiatric Association Annual Meeting; 2004 May 1–6: New York Lasser R, Bossie CA, Zhu Y, et al. Long-acting risperidone in young adults with schizophrenia or schizoaffective disorder [abstract]. 157th American Psychiatric Association Annual Meeting; 2004 May 1–6: New York
50.
Zurück zum Zitat Emsley R, Oosthuizen P, Koem L, et al. A trial of risperidone long-acting injectable in first episode psychosis [abstract]. American Psychiatric Association Annual Meeting; 2005 May 21–26: Atlanta (GA) Emsley R, Oosthuizen P, Koem L, et al. A trial of risperidone long-acting injectable in first episode psychosis [abstract]. American Psychiatric Association Annual Meeting; 2005 May 21–26: Atlanta (GA)
51.
Zurück zum Zitat Emsley R, Oosthuizen P, Koem L, et al. Safety and efficacy of long-acting risperidone as a first-line treatment for first-episode psychosis: 6-month interim analysis [abstract]. XIIIth Biennial Winter Workshop of Schizophrenia Research; 2006 Feb 4–10: Davos Emsley R, Oosthuizen P, Koem L, et al. Safety and efficacy of long-acting risperidone as a first-line treatment for first-episode psychosis: 6-month interim analysis [abstract]. XIIIth Biennial Winter Workshop of Schizophrenia Research; 2006 Feb 4–10: Davos
52.
Zurück zum Zitat Möller H, Llorca PM, Sachetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005; 20: 121–30PubMedCrossRef Möller H, Llorca PM, Sachetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005; 20: 121–30PubMedCrossRef
53.
Zurück zum Zitat Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second generation antipsychotic. J Clin Psychiatry 2003; 64: 1250–7PubMedCrossRef Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second generation antipsychotic. J Clin Psychiatry 2003; 64: 1250–7PubMedCrossRef
54.
Zurück zum Zitat American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC. American Psychiatric Association, 1994 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC. American Psychiatric Association, 1994
55.
Zurück zum Zitat Malla A, Binder C, Chue P. Comparison of long-acting injectable risperidone and oral novel antipsychotic drugs for treatment in early phase of schizophrenia spectrum psychosis [abstract]. 61st Annual Convention Society of Biological Psychiatry; 2006 May 18–20: Toronto (ON) Malla A, Binder C, Chue P. Comparison of long-acting injectable risperidone and oral novel antipsychotic drugs for treatment in early phase of schizophrenia spectrum psychosis [abstract]. 61st Annual Convention Society of Biological Psychiatry; 2006 May 18–20: Toronto (ON)
56.
Zurück zum Zitat Rummel C, Hamann J, Kissling W, et al. New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev 2003; (4): CD004410 Rummel C, Hamann J, Kissling W, et al. New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev 2003; (4): CD004410
57.
Zurück zum Zitat Bradford DW, Perkins DO, Lieberman JA. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 2003; 63(21): 2265–83PubMedCrossRef Bradford DW, Perkins DO, Lieberman JA. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 2003; 63(21): 2265–83PubMedCrossRef
58.
Zurück zum Zitat Lambert M, Conus P, Lambert T, et al. Pharmacotherapy of first-episode psychosis. Expert Opin Pharmacother 2003; 4(5): 717–50PubMedCrossRef Lambert M, Conus P, Lambert T, et al. Pharmacotherapy of first-episode psychosis. Expert Opin Pharmacother 2003; 4(5): 717–50PubMedCrossRef
59.
Zurück zum Zitat Ohlsen RI, O’Toole MS, Purvis RG, et al. Clinical effectiveness in first-episode patients. Eur Neuropsychopharmacol 2004; 14(4): S445–51PubMedCrossRef Ohlsen RI, O’Toole MS, Purvis RG, et al. Clinical effectiveness in first-episode patients. Eur Neuropsychopharmacol 2004; 14(4): S445–51PubMedCrossRef
60.
Zurück zum Zitat Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 2005; 65(8): 1113–38PubMedCrossRef Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 2005; 65(8): 1113–38PubMedCrossRef
61.
Zurück zum Zitat Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. HGDH Study Group. Am J Psychiatry 2003; 160(8): 1396–404 Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. HGDH Study Group. Am J Psychiatry 2003; 160(8): 1396–404
62.
Zurück zum Zitat Chue PS, D’Hoore P, Ramstack JM. Sustained drug delivery optimizes long-term treatment of patients with schizophrenia. Acta Neuropsychiatrica 2004; 16(6): 319–26CrossRef Chue PS, D’Hoore P, Ramstack JM. Sustained drug delivery optimizes long-term treatment of patients with schizophrenia. Acta Neuropsychiatrica 2004; 16(6): 319–26CrossRef
63.
Zurück zum Zitat Chue P. Compliance and convenience: do physicians and patients see depot medication differently? Acta Neuropsychiatrica 2004; 16: 314–38CrossRef Chue P. Compliance and convenience: do physicians and patients see depot medication differently? Acta Neuropsychiatrica 2004; 16: 314–38CrossRef
64.
Zurück zum Zitat Leal A, Rosillon D, Mehnert A, et al. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf 2004; 13: 811–6PubMedCrossRef Leal A, Rosillon D, Mehnert A, et al. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf 2004; 13: 811–6PubMedCrossRef
65.
Zurück zum Zitat Patel MX, De Zoysa N, Baker D, et al. Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs 2005; 12(2): 237–44PubMedCrossRef Patel MX, De Zoysa N, Baker D, et al. Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs 2005; 12(2): 237–44PubMedCrossRef
66.
Zurück zum Zitat Patel MX, Nikolaou V, David AS. Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003; 33: 83–9PubMedCrossRef Patel MX, Nikolaou V, David AS. Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003; 33: 83–9PubMedCrossRef
67.
Zurück zum Zitat Chue P, Llorca P, Duchesne I, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 2005; 5: 266–74 Chue P, Llorca P, Duchesne I, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 2005; 5: 266–74
68.
Zurück zum Zitat Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001; 179: 300–7PubMedCrossRef Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001; 179: 300–7PubMedCrossRef
69.
Zurück zum Zitat Svedberg B, Backenroth-Ohsako G, Lutzen K. On the path to recovery: patients’ experiences of treatment with long-acting injections of antipsychotic medication. Int J Ment Health Nurs 2003; 12(2): 110–8PubMedCrossRef Svedberg B, Backenroth-Ohsako G, Lutzen K. On the path to recovery: patients’ experiences of treatment with long-acting injections of antipsychotic medication. Int J Ment Health Nurs 2003; 12(2): 110–8PubMedCrossRef
70.
Zurück zum Zitat Fleischhacker WW, Lasser R, Mehnert A. Perceived functioning and well-being and association with psychiatric symptomatology in clinically stable schizophrenia patients treated with long-acting risperidone for 1 year. Br J Psychiatry 2005; 187: 131–6PubMedCrossRef Fleischhacker WW, Lasser R, Mehnert A. Perceived functioning and well-being and association with psychiatric symptomatology in clinically stable schizophrenia patients treated with long-acting risperidone for 1 year. Br J Psychiatry 2005; 187: 131–6PubMedCrossRef
71.
Zurück zum Zitat Nasrallah HA, Duchesne I, Mehnert A, et al. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 2004; 65: 531–6PubMedCrossRef Nasrallah HA, Duchesne I, Mehnert A, et al. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 2004; 65: 531–6PubMedCrossRef
72.
Zurück zum Zitat Lindenmayer JP, Jarboe K, Bossie CA, et al. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol 2005; 20(4): 213–21PubMedCrossRef Lindenmayer JP, Jarboe K, Bossie CA, et al. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol 2005; 20(4): 213–21PubMedCrossRef
73.
Zurück zum Zitat Mannaert E, Vermeulen A, Remmerie B, et al. Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. Encephale 2005; 31(5): 609–15PubMedCrossRef Mannaert E, Vermeulen A, Remmerie B, et al. Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. Encephale 2005; 31(5): 609–15PubMedCrossRef
74.
Zurück zum Zitat Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003; 64(16): 18–23PubMed Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003; 64(16): 18–23PubMed
75.
Zurück zum Zitat Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D 2005; 6(3): 129–37PubMedCrossRef Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D 2005; 6(3): 129–37PubMedCrossRef
76.
Zurück zum Zitat Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomised trial. Early Psychosis Global Working Group. Am J Psychiatry 2005; 162(5): 947–53 Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomised trial. Early Psychosis Global Working Group. Am J Psychiatry 2005; 162(5): 947–53
77.
Zurück zum Zitat Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999; 25: 721–9CrossRef Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999; 25: 721–9CrossRef
78.
Zurück zum Zitat Lambert T. Selecting patients for novel long-acting antipsychotic therapy. Australas Psychiatry 2006; 14(1): 38–42PubMed Lambert T. Selecting patients for novel long-acting antipsychotic therapy. Australas Psychiatry 2006; 14(1): 38–42PubMed
79.
Zurück zum Zitat Fraser R, Berger G, Killackey E, et al. Emerging psychosis in young people: part 3. Key issues for prolonged recovery. Australian Family Physician 2006; 35(5): 329–33 Fraser R, Berger G, Killackey E, et al. Emerging psychosis in young people: part 3. Key issues for prolonged recovery. Australian Family Physician 2006; 35(5): 329–33
Metadaten
Titel
Long-Acting Formulations of Atypical Antipsychotics
Time to Reconsider When to Introduce Depot Antipsychotics
verfasst von
Dr Pierre Chue
Robin Emsley
Publikationsdatum
01.06.2007
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 6/2007
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200721060-00001

Weitere Artikel der Ausgabe 6/2007

CNS Drugs 6/2007 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.